NASDAQ:CERE

Cerevel Therapeutics (CERE) Stock Forecast, Price & News

$33.66

+1.06 (+3.25%)

(As of 02:33 PM ET)

Compare

Today's Range: $32.36
▼
$33.74
50-Day Range: $23.90
▼
$34.00
52-Week Range: $22.10
▼
$41.46

Volume: 213,761 shs
Average Volume: 579,686 shs
Market Capitalization: $5.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $34.80

Cerevel Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 3.4% Upside
$34.80 Price Target
Short Interest: Bearish
6.99% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.08
Based on 8 Articles This Week
Insider Trading: Selling Shares
$4.52 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.70) to ($2.90) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.23 out of 5 stars

Medical Sector

954th out of 981 stocks

Pharmaceutical Preparations Industry

467th out of 481 stocks

2.3

Analyst's Opinion

Consensus Rating
Cerevel Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 8 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $34.80, Cerevel Therapeutics has a forecasted upside of 3.4% from its current price of $33.66.
Amount of Analyst Coverage
Cerevel Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
6.99% of the float of Cerevel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Cerevel Therapeutics has a short interest ratio ("days to cover") of 7.1.
Change versus previous month
Short interest in Cerevel Therapeutics has recently increased by 5.83%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cerevel Therapeutics does not currently pay a dividend.
Dividend Growth
Cerevel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CERE.

2.3

News and Social Media Coverage

News Sentiment
Cerevel Therapeutics has a news sentiment score of 0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Cerevel Therapeutics this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for CERE on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.
MarketBeat Follows
2 people have added Cerevel Therapeutics to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cerevel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,518,940.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Cerevel Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Cerevel Therapeutics are expected to decrease in the coming year, from ($2.70) to ($2.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cerevel Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cerevel Therapeutics is -13.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cerevel Therapeutics has a P/B Ratio of 10.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cerevel Therapeutics (NASDAQ:CERE) Stock

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Receive CERE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cerevel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CERE Stock News Headlines

June 7, 2023 | americanbankingnews.com

Mark Bodenrader Sells 1,895 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stock

June 7, 2023 | americanbankingnews.com

N Anthony Coles Sells 50,000 Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Stock

June 8, 2023 | Edge On The Street (Ad)

The Real Problem With "Made in America" Lithium

Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.

June 4, 2023 | seekingalpha.com

Cerevel: High Priced Stock Doing Interesting Science

May 24, 2023 | 247wallst.com

Goldman Sachs Maintains Cerevel Therapeutics Neutral Recommendation

May 24, 2023 | msn.com

Goldman Sachs Maintains Cerevel Therapeutics Holdings (CERE) Neutral Recommendation

May 23, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Icecure Medical (ICCM)

May 23, 2023 | americanbankingnews.com

Brokerages Set Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Price Target at $34.80

June 8, 2023 | Edge On The Street (Ad)

New "Mined in America" Lithium Opportunities?

The average electric vehicle needs 138 pounds of lithium carbonate for its battery components. But China currently controls the entire lithium supply chain.

May 16, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Its Buy Rating for Athira Pharma (ATHA)

May 16, 2023 | it.tmcnet.com

Google Cloud Launches AI-powered Solutions to Safely Accelerate Drug Discovery and Precision Medicine

May 16, 2023 | msn.com

Google Cloud launches A.I.-powered tools to accelerate drug discovery, precision medicine

May 12, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Astria Therapeutics (ATXS), Nkarta (NKTX)

May 10, 2023 | markets.businessinsider.com

Cerevel Therapeutics Appoints Susan Altschuller As Its New CFO

May 10, 2023 | finance.yahoo.com

Cerevel Therapeutics Appoints Susan Altschuller, Ph.D. as Chief Financial Officer

May 9, 2023 | msn.com

Mizuho Maintains Cerevel Therapeutics Holdings (CERE) Neutral Recommendation

May 9, 2023 | americanbankingnews.com

Q2 2023 EPS Estimates for Cerevel Therapeutics Holdings, Inc. Lifted by Analyst (NASDAQ:CERE)

May 8, 2023 | americanbankingnews.com

Mizuho Boosts Cerevel Therapeutics (NASDAQ:CERE) Price Target to $29.00

May 7, 2023 | seekingalpha.com

Cerevel Therapeutics Holdings, Inc. 2023 Q1 - Results - Earnings Call Presentation

May 5, 2023 | msn.com

Wells Fargo Upgrades Cerevel Therapeutics Holdings (CERE)

May 4, 2023 | americanbankingnews.com

Short Interest in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Drops By 6.8%

May 4, 2023 | americanbankingnews.com

Wells Fargo & Company Upgrades Cerevel Therapeutics (NASDAQ:CERE) to "Overweight"

May 3, 2023 | seekingalpha.com

Cerevel Therapeutics GAAP EPS of -$0.67 in-line

May 3, 2023 | markets.businessinsider.com

Mizuho Securities Keeps Their Hold Rating on Cerevel Therapeutics Holdings (CERE)

May 3, 2023 | nasdaq.com

Cerevel Therapeutics Appoints Ron Renaud As CEO; Tony Coles To Remain Chairperson

May 3, 2023 | markets.businessinsider.com

Cerevel Therapeutics Holdings Inc. Q1 loss increases in line with estimates

May 3, 2023 | msn.com

Cerevel Therapeutics Hldg: Q1 Earnings Insights

See More Headlines

CERE Price History

30 days | 90 days | 365 days | Advanced Chart

CERE Company Calendar

Last Earnings: 5/03/2023
Today: 6/08/2023
Next Earnings (Estimated): 8/07/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Coal & Consumable Fuels
Sector: Medical
Current Symbol: NASDAQ:CERE
CUSIP: 15677310
CIK: 767884
Web: ceres.net
Phone: 844-304-2048
Fax: N/A
Employees: 200
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $34.80
High Stock Price Forecast: $46.00
Low Stock Price Forecast: $22.00
Forecasted Upside/Downside: +6.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-351,510,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -77.15%
Return on Assets: -42.60%

Debt

Debt-to-Equity Ratio: 0.78
Current Ratio: 13.35
Quick Ratio: 13.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.33 per share
Price / Book: 9.79

Miscellaneous

Outstanding Shares: 156,830,000
Free Float: 148,835,000
Market Cap: $5.11 billion
Optionable: Not Optionable
Beta: 1.47

Key Executives

Dr. N. Anthony Coles Jr. (Age 62)
M.P.H., Exec. Chairman & CEO
Comp: $1.01M

Mr. Abraham N. Ceesay M.B.A. (Age 44)
Pres
Comp: $776.64k

Mr. Mark Bodenrader (Age 49)
Interim CFO, VP of Fin. & Chief Accounting Officer
Comp: $440.89k

Mr. Scott M. Akamine J.D. (Age 37)
Chief Legal Officer & Corp. Sec.
Comp: $444.74k

Dr. Ramiro Sanchez M.D. (Age 61)
Chief Medical Officer
Comp: $716.29k

Dr. John J. Renger Ph.D. (Age 53)
Chief Scientific Officer

Mr. Matthew Calistri
VP of Investor Relations

Mr. Kenneth A. DiPietro (Age 63)
Chief HR Officer

Ms. Kathleen Tregoning M.A. (Age 51)
Chief Corp. Affairs Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CERE Stock - Frequently Asked Questions

Should I buy or sell Cerevel Therapeutics stock right now?: 12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cerevel Therapeutics in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CERE shares.
View CERE analyst ratings or view top-rated stocks.
What is Cerevel Therapeutics' stock price forecast for 2023?: 12 equities research analysts have issued 1-year target prices for Cerevel Therapeutics' stock. Their CERE share price forecasts range from $22.00 to $46.00. On average, they predict the company's share price to reach $34.80 in the next twelve months. This suggests a possible upside of 6.7% from the stock's current price.
View analysts price targets for CERE or view top-rated stocks among Wall Street analysts.
How have CERE shares performed in 2023?: Cerevel Therapeutics' stock was trading at $31.54 at the start of the year. Since then, CERE stock has increased by 3.4% and is now trading at $32.60.
View the best growth stocks for 2023 here.
Are investors shorting Cerevel Therapeutics?: Cerevel Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 4,720,000 shares, an increase of 5.8% from the April 30th total of 4,460,000 shares. Based on an average trading volume of 666,600 shares, the short-interest ratio is currently 7.1 days. Approximately 7.0% of the company's stock are short sold.
View Cerevel Therapeutics' Short Interest.
When is Cerevel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 7th 2023.
View our CERE earnings forecast.
How were Cerevel Therapeutics' earnings last quarter?: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) posted its earnings results on Wednesday, May, 3rd. The biotechnology company reported ($0.67) EPS for the quarter, meeting analysts' consensus estimates of ($0.67). During the same quarter in the prior year, the business posted ($0.46) EPS.
What ETFs hold Cerevel Therapeutics' stock?: ETFs with the largest weight of Cerevel Therapeutics (NASDAQ:CERE) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), BlackRock Future Health ETF (BMED) and AI Powered Equity ETF (AIEQ).

What other stocks do shareholders of Cerevel Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cerevel Therapeutics investors own include Precigen (PGEN), Arena Pharmaceuticals (ARNA), CTI BioPharma (CTIC), Achillion Pharmaceuticals (ACHN), Alpha Natural Resources (ANRZQ), Cenveo (CVO), Hess (HES), Palatin Technologies (PTN), Aeterna Zentaris (AEZS) and Avid Bioservices (CDMO).
What is Cerevel Therapeutics' stock symbol?: Cerevel Therapeutics trades on the NASDAQ under the ticker symbol "CERE."
Who are Cerevel Therapeutics' major shareholders?: Cerevel Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Price T Rowe Associates Inc. MD (3.06%), BlackRock Inc. (2.86%), State Street Corp (2.00%), Federated Hermes Inc. (1.23%) and Geode Capital Management LLC (0.80%). Insiders that own company stock include Abraham Ceesay, Deval L Patrick, Gabrielle Sulzberger, John Renger, Mark Bodenrader, N Anthony Coles and Perceptive Advisors Llc.
View institutional ownership trends.
How do I buy shares of Cerevel Therapeutics?: Shares of CERE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cerevel Therapeutics' stock price today?: One share of CERE stock can currently be purchased for approximately $32.60.
How much money does Cerevel Therapeutics make?: Cerevel Therapeutics (NASDAQ:CERE) has a market capitalization of $5.11 billion. The biotechnology company earns $-351,510,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.
How many employees does Cerevel Therapeutics have?: The company employs 200 workers across the globe.
How can I contact Cerevel Therapeutics?: Cerevel Therapeutics' mailing address is 1535 Rancho Conejo Blvd, THOUSAND OAKS, CA 91320-1440, United States. The official website for the company is ceres.net. The biotechnology company can be reached via phone at 844-304-2048 or via email at ir@cerevel.com.

This page (NASDAQ:CERE) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial